{"id":"pde5-inhibitor-tadalafil","safety":{"commonSideEffects":[{"rate":"15–20","effect":"Headache"},{"rate":"10–15","effect":"Dyspepsia"},{"rate":"10–15","effect":"Flushing"},{"rate":"5–10","effect":"Myalgia"},{"rate":"5–10","effect":"Nasal congestion"},{"rate":"5–10","effect":"Back pain"}]},"_chembl":{"chemblId":"CHEMBL779","moleculeType":"Small molecule","molecularWeight":"389.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PDE5 inhibitors block the enzyme that degrades cyclic guanosine monophosphate (cGMP), allowing cGMP to accumulate in vascular and smooth muscle tissues. This leads to increased vasodilation and improved blood flow. In the context of cancer therapy at Regina Elena Cancer Institute, tadalafil may be investigated for its potential to enhance tumor perfusion, improve drug delivery, or modulate the tumor microenvironment.","oneSentence":"Tadalafil inhibits phosphodiesterase type 5 (PDE5), increasing cyclic GMP levels to promote vasodilation and smooth muscle relaxation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:25:57.238Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer therapy (investigational; specific indication unclear from available information)"}]},"trialDetails":[{"nctId":"NCT07466030","phase":"PHASE1","title":"Tadalafil 5 mg on Storage Lower Urinary Tract Symptoms After Anatomical Endoscopic Enucleation of the Prostate","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-03-01","conditions":"BPH (Benign Prostatic Hyperplasia)","enrollment":40},{"nctId":"NCT06350773","phase":"NA","title":"Phosphodiesterase Type 5 Inhibitors in Patients With Group 2 Pulmonary Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beni-Suef University","startDate":"2023-06-10","conditions":"Group 2 Pulmonary Hypertension","enrollment":48},{"nctId":"NCT03229889","phase":"PHASE4","title":"Trial of Tadalafil, Tamsulosin and Combination for Access Sheath Deployment","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2017-06-07","conditions":"Nephrolithiasis","enrollment":220},{"nctId":"NCT05937854","phase":"PHASE2","title":"Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-04-01","conditions":"Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension, Dyspnea","enrollment":126},{"nctId":"NCT07206706","phase":"PHASE1, PHASE2","title":"Efficacy and Tolerability of Tadalafil Versus Darifenacin in Management of Ureteric Stent-Related LUTS","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-05-01","conditions":"Management of Ureteric Stent Related LUTS and Pain","enrollment":150},{"nctId":"NCT05844462","phase":"PHASE3","title":"Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-02-01","conditions":"Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease","enrollment":200},{"nctId":"NCT07312955","phase":"NA","title":"Solifenacin Plus Tadalafil vs Solifenacin Alone for Overactive Bladder in Females","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2025-05-15","conditions":"Overactive Bladder","enrollment":80},{"nctId":"NCT07245680","phase":"PHASE3","title":"COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-01-15","conditions":"Pulmonary Arterial Hypertension (PAH), Comorbidities, Cardiovascular Disease (CVD)","enrollment":186},{"nctId":"NCT07172815","phase":"PHASE2","title":"PDE5 Inhibitor for Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"Imperial College London","startDate":"2025-09","conditions":"Alzheimer Disease","enrollment":244},{"nctId":"NCT05039086","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-09-01","conditions":"Pulmonary Arterial Hypertension","enrollment":13021},{"nctId":"NCT06717711","phase":"PHASE3","title":"Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers","status":"RECRUITING","sponsor":"Regina Elena Cancer Institute","startDate":"2024-08-31","conditions":"Prostate Carcinoma, Erectile Function, Genito Urinary Cancer","enrollment":158},{"nctId":"NCT05458232","phase":"","title":"Use of a Phosphodiesterase Type 5 Inhibitor to Improve Anabolic Resistance in Older Adults","status":"WITHDRAWN","sponsor":"University of Arkansas","startDate":"2023-01-20","conditions":"Sarcopenia","enrollment":""},{"nctId":"NCT06442020","phase":"NA","title":"Low Intensity Shock Wave Therapy in the Rehabilitation Treatment of Erectile Dysfunction After Robotic Radical Prostatectomy.","status":"RECRUITING","sponsor":"Regina Elena Cancer Institute","startDate":"2023-09-15","conditions":"Erectile Dysfunction","enrollment":158},{"nctId":"NCT05487755","phase":"PHASE3","title":"Investigational and Comparative Study in the Management of Diabetic Nephropathy","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-02-01","conditions":"Diabetic Nephropathy Type 2","enrollment":90},{"nctId":"NCT06317805","phase":"PHASE4","title":"Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients","status":"RECRUITING","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2023-12-06","conditions":"Pulmonary Arterial Hypertension","enrollment":110},{"nctId":"NCT02611258","phase":"PHASE2","title":"Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs","status":"COMPLETED","sponsor":"Andrea M. Isidori","startDate":"2016-07","conditions":"Cushing's Syndrome Cardiomyopathy","enrollment":18},{"nctId":"NCT02611336","phase":"PHASE2","title":"Endocrine Cardiomyopathy: Response to Cyclic GMP PDE5 Inhibitors in Acromegaly Cardiomyopathy","status":"COMPLETED","sponsor":"Andrea M. Isidori","startDate":"2016-07","conditions":"Acromegaly Cardiomyopathy","enrollment":15},{"nctId":"NCT05823506","phase":"NA","title":"Efficacy and Safety of Focused Shockwave Therapy Plus Tadalafil vs Tadalafil Alone in Patient With Erectile Dysfunction","status":"UNKNOWN","sponsor":"Saint Petersburg State University, Russia","startDate":"2023-02-01","conditions":"Erectile Dysfunction","enrollment":36},{"nctId":"NCT02565030","phase":"","title":"Chronic Thrombo-embolic Pulmonary Hypertension: Classification and Long Term Outcome","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2015-02","conditions":"Chronic Thromboembolic Pulmonary Hypertension, Idiopathic Pulmonary Arterial Hypertension","enrollment":1200},{"nctId":"NCT05236634","phase":"NA","title":"(Phosphodiesterase 5 Inhibitors & α-blockers): Single Versus Combined Therapy in Benign Prostatic Hyperplasia","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-05-01","conditions":"Benign Prostatic Hyperplasia","enrollment":120},{"nctId":"NCT01824290","phase":"PHASE3","title":"A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-02-05","conditions":"Hypertension, Pulmonary","enrollment":35},{"nctId":"NCT05043896","phase":"NA","title":"The Effect of Combination Therapy Using Li-ESWT and PDE-5 Inhibitor in Patients With Erectile Dysfunction","status":"COMPLETED","sponsor":"Dr. Soetomo General Hospital","startDate":"2019-12-10","conditions":"Erectile Dysfunction","enrollment":30},{"nctId":"NCT02252367","phase":"PHASE4","title":"Effect of 12 Weeks Treatment With Tadalafil vs Placebo on Lower Urinary Tract Symptoms","status":"COMPLETED","sponsor":"University of Florence","startDate":"2015-12","conditions":"Prostatic Hyperplasia, Lower Urinary Tract Symptoms","enrollment":86},{"nctId":"NCT02103088","phase":"NA","title":"Sexual and Urological Rehabilitation to Men Operated for Prostate Cancer and Their Partners","status":"COMPLETED","sponsor":"Danish Cancer Society","startDate":"2014-05","conditions":"Prostate Cancer","enrollment":72},{"nctId":"NCT02601989","phase":"PHASE2","title":"Effects on Insulin Resistance With Tadalafil in Type 2 Diabetes - a Double-blind, Placebo-controlled Crossover Study","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2015-11","conditions":"Diabetes Mellitus, Type 2","enrollment":23},{"nctId":"NCT02484807","phase":"","title":"Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients With PAH","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"2015-05","conditions":"Pulmonary Arterial Hypertension","enrollment":125},{"nctId":"NCT03918993","phase":"","title":"Effects of Tadalafil on LMR and MHR in Patients With ED","status":"COMPLETED","sponsor":"Samsun Liv Hospital","startDate":"2019-02-14","conditions":"Erectile Dysfunction, Inflammation","enrollment":62},{"nctId":"NCT00867815","phase":"PHASE4","title":"PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)","status":"TERMINATED","sponsor":"Bayer","startDate":"2009-07-13","conditions":"Anterior Ischemic Optic Neuropathy","enrollment":10},{"nctId":"NCT01374217","phase":"PHASE2","title":"Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2012-04","conditions":"Multiple Myeloma","enrollment":14},{"nctId":"NCT01131104","phase":"","title":"A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-05","conditions":"Nonarteritic Anterior Ischemic Optic Neuropathy","enrollment":345},{"nctId":"NCT00931528","phase":"PHASE3","title":"Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2009-11","conditions":"Prostate Cancer, Sexual Dysfunction","enrollment":242},{"nctId":"NCT01444651","phase":"PHASE3","title":"A Trial of Tadalafil and Glycemic Traits","status":"COMPLETED","sponsor":"Thomas J. Wang, MD","startDate":"2011-08","conditions":"Cardiovascular Disease, Insulin Resistance, Glucose Intolerance","enrollment":73},{"nctId":"NCT01266265","phase":"","title":"Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2010-12","conditions":"Pulmonary Arterial Hypertension","enrollment":1333},{"nctId":"NCT00843635","phase":"NA","title":"Tadalafil in Treating Patients Undergoing Surgery for Cancer of the Oral Cavity or Oropharynx","status":"COMPLETED","sponsor":"Donald T. Weed","startDate":"2008-09","conditions":"Head and Neck Cancer","enrollment":35},{"nctId":"NCT00506701","phase":"NA","title":"Effect of Tadalafil in Chronic Obstructive Lung Disease Patients Suffering From Secondary Pulmonary Hypertension","status":"WITHDRAWN","sponsor":"Herlev Hospital","startDate":"2008-02","conditions":"Chronic Obstructive Lung Disease","enrollment":""},{"nctId":"NCT01580501","phase":"PHASE1","title":"PDE Inhibitors in DMD Study (Acute Dosing Study)","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2012-03","conditions":"Duchenne Muscular Dystrophy","enrollment":12},{"nctId":"NCT00549302","phase":"PHASE3","title":"Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2005-12","conditions":"Hypertension, Pulmonary","enrollment":357},{"nctId":"NCT01063855","phase":"PHASE3","title":"Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-04","conditions":"Erectile Dysfunction, Sexual Dysfunction","enrollment":495},{"nctId":"NCT01130532","phase":"PHASE4","title":"A Study in Erectile Dysfunction","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-08","conditions":"Erectile Dysfunction","enrollment":623},{"nctId":"NCT01743911","phase":"NA","title":"Tadalafil Effects in Left Ventricle Diastolic Dysfunction in Resistant Hypertensive Patients","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2010-09","conditions":"Hypertension","enrollment":20},{"nctId":"NCT01122264","phase":"PHASE4","title":"A Study in Patients With Erectile Dysfunction","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-05","conditions":"Erectile Dysfunction","enrollment":770},{"nctId":"NCT00617305","phase":"PHASE4","title":"Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-04","conditions":"Pulmonary Arterial Hypertension","enrollment":38},{"nctId":"NCT01564303","phase":"NA","title":"Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN)","status":"UNKNOWN","sponsor":"The Nazareth Hospital","startDate":"2012-05","conditions":"Contrast Media Induced Nephropathy","enrollment":80},{"nctId":"NCT00836693","phase":"PHASE3","title":"Effect of Tadalafil Once a Day in Men With Erectile Dysfunction","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-01","conditions":"Erectile Dysfunction","enrollment":217},{"nctId":"NCT00734604","phase":"PHASE3","title":"A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-08","conditions":"Erectile Dysfunction","enrollment":378},{"nctId":"NCT01200732","phase":"PHASE2","title":"Phosphodiesterase-5 Inhibitor in Eisenmenger Syndrome","status":"COMPLETED","sponsor":"Govind Ballabh Pant Hospital","startDate":"2008-02","conditions":"Eisenmenger Syndrome","enrollment":28},{"nctId":"NCT00244023","phase":"PHASE3","title":"Co-Administering Testosterone With PDE5 Inhibitors in ED Patients Non Responders to PDE5 Inhibitors Alone","status":"COMPLETED","sponsor":"SELARL du Dr Jacques BUVAT","startDate":"2005-10","conditions":"Erectile Dysfunction, Hypogonadism","enrollment":173},{"nctId":"NCT00705588","phase":"PHASE4","title":"Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids.","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2008-08","conditions":"Pulmonary Arterial Hypertension","enrollment":30},{"nctId":"NCT00125918","phase":"PHASE3","title":"PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2005-08","conditions":"Pulmonary Hypertension","enrollment":406}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":66,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PDE5 inhibitor (tadalafil)","genericName":"PDE5 inhibitor (tadalafil)","companyName":"Regina Elena Cancer Institute","companyId":"regina-elena-cancer-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tadalafil inhibits phosphodiesterase type 5 (PDE5), increasing cyclic GMP levels to promote vasodilation and smooth muscle relaxation. Used for Cancer therapy (investigational; specific indication unclear from available information).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}